Pifoxime

Summary

Pifoxime (CHEMBL1998966) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 276.33 Da · C15H20N2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1998966
Name	Pifoxime
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	9570475
Molecular formula	C15H20N2O3
Molecular weight	276.33
InChIKey	XUDSQIDNHJMBBW-FOWTUZBSSA-N

SMILES: C/C(=N\O)/C1=CC=C(C=C1)OCC(=O)N2CCCCC2

IUPAC name: 2-[4-[(E)-N-hydroxy-C-methylcarbonimidoyl]phenoxy]-1-piperidin-1-ylethanone

Also known as: Pifoxima, Pifoxime, SID124894227, SID144206861, PIFOXIME

Patent coverage: 797 distinct patent families (2,918 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).